Cite
HARVARD Citation
Cherney, D. et al. (2020). Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet. 8 (7), pp. 582-593. [Online].